Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy

被引：3
|
作者：
Nakase, H. [1 ]
Matsuura, M. [1 ]
Uza, N. [1 ]
Chiba, T. [1 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2011年 / 33卷 / 08期
关键词：
D O I：
10.1111/j.1365-2036.2011.04587.x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：979 / 980
页数：2
相关论文
共 50 条
  • [1] Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy: authors' reply
    Tozer, P. J.
    Burling, D.
    Gupta, A.
    Phillips, R. K. S.
    Hart, A. L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (08) : 980 - 981
  • [2] Administration of anti-IL-12 mAb in Crohn's disease patients leads to downmodulation of p40 expression and IL-12/IL-23 derived cytokines
    Fuss, IJ
    Becker, C
    Yang, ZQ
    Groden, C
    Hornung, R
    Nikolaev, A
    Heller, F
    Neurath, M
    Strober, W
    Mannon, PJ
    GASTROENTEROLOGY, 2005, 128 (04) : A118 - A118
  • [3] Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis
    Martin, Roland
    LANCET NEUROLOGY, 2008, 7 (09): : 765 - 766
  • [4] Anti IL-12/IL-23 p40 therapy inhibits epidermal activation in uninvolved psoriatic skin
    Baerveldt, Ewout
    Onderdijk, Armanda
    Kant, Marius
    Florencia, Eddy
    Gudjonsson, Johann
    Thio, Bing
    Laman, Jon
    Prens, Errol
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S44 - S44
  • [5] Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a
    Leonardi, Craig L.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2016, 35 : S74 - S77
  • [6] Ovarian follicular concentration of IL-12, IL-15, IL-18 and p40 subunit of IL-12 and IL-23
    Vujisic, Sanja
    Lepej, Snjezana Zidovec
    Emedi, Ivana
    Bauman, Renato
    Remenar, Anica
    Tiljak, Mirjana Kujundzic
    HUMAN REPRODUCTION, 2006, 21 (10) : 2650 - 2655
  • [7] Biological functions of IL-12 p40 homodimer and monomer are different from that of IL-12 p70 and IL-23
    Jana, M
    Dasgupta, S
    Dudley, TM
    Liu, X
    Pahan, K
    JOURNAL OF NEUROCHEMISTRY, 2005, 94 : 90 - 90
  • [8] The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn's disease refractory or intolerant to anti-TNF: a multicentre Italian study
    Gubbiotti, A.
    Barberio, B.
    Zingone, F.
    D'Inca, R.
    Bertani, L.
    Ferronato, A.
    Urbano, M. T.
    Sablich, R.
    Savarino, E. V.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S379 - S379
  • [9] ASSOCIATION BETWEEN DISEASE ACTIVITY AND IL-17A/F, IL-23 AND IL-12/23 (p40) PRODUCTION BY PERIPHERAL BLOOD T LYMPHOCYTES IN BEHCET'S DISEASE
    Yucel, Aysegul Atak
    Sonmez, Cemile
    Yesii, Turan Hilmi
    Kucuk, Hamit
    Mercan, Ridvan
    Yucel, Eftal Ahmet
    Goker, Berna
    Tufan, Muge Aydin
    Demirel, Gulderen Yanikkaya
    Sezgin, Berna
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [10] Cutaneous Infarction Under IL-12/23 p40 Inhibition: A Cautionary Note
    Lipsker, Dan
    Lutz, Virginie
    ARCHIVES OF DERMATOLOGY, 2011, 147 (11) : 1344 - 1345
12345